2 studies found for:    21816833 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
Conditions: Chronic Lymphocytic Leukemia (CLL);   Lymphoma, Non-Hodgkin (NHL);   Acute Myeloid Leukemia (AML);   Multiple Myeloma (MM)
Intervention: Drug: CAL-101
2 Active, not recruiting Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Conditions: Indolent Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Mantle Cell Lymphoma
Interventions: Drug: Idelalisib;   Drug: Rituximab;   Drug: Bendamustine;   Drug: Ofatumumab;   Drug: Fludarabine;   Drug: Everolimus;   Drug: Bortezomib;   Drug: Chlorambucil;   Drug: Lenalidomide

Indicates status has not been verified in more than two years